ATXN8 Gene
Introduction <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>Ensembl ID </td>UniProt ID </td>Gene Type </td>OMIM </td>
...
ATXN8 Gene
Introduction <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>Ensembl ID </td>UniProt ID </td>Gene Type </td>OMIM </td>
The ATXN8 gene (Ataxin-8) encodes a polyglutamine (polyQ) expansion protein that causes spinocerebellar ataxia type 8 (SCA8) when the CAG trinucleotide repeat expands abnormally. SCA8 is a progressive cerebellar ataxia characterized by slowly progressive incoordination, speech difficulties, and various neurological manifestations. The ataxin-8 protein is widely expressed in the nervous system and has complex normal functions that are disrupted by polyQ expansion. [@spinocerebellar2023]
Gene Overview
Protein Product Ataxin-8 is a protein of approximately 343 amino acids in its normal form. The protein contains a polyglutamine (polyQ) tract near its N-terminus, which becomes pathologically expanded in SCA8. The length of the polyQ tract determines disease onset and severity. [@ataxin2022]
Structure
PolyQ Tract : N-terminal glutamine repeats (normal: 17-50, pathogenic: 71-1300+)Axin Domain : Involved in protein-protein interactionsNuclear Localization Signals : Potential nuclear functionHEAT Repeats : Protein interaction motifsFunction Normal ataxin-8 functions are not fully understood, but research suggests:
Transcriptional Regulation : May modulate gene expressionCell Signaling : Involved in various signaling pathwaysNeuronal Development : Important for proper brain developmentRNA Processing : Some evidence for RNA-binding capabilitySynaptic Function : May affect neurotransmitter release [@polyq2021]
Expression Pattern
Broad expression in central nervous system
High expression in cerebellum
Present in Purkinje cells
Found in cerebral cortex and brainstem
Disease Associations
Spinocerebellar Ataxia Type 8 (SCA8) SCA8 is an autosomal dominant trinucleotide repeat disorder:
Onset : Usually adulthood (30-40 years)Progression : Slowly progressive over decadesSymptoms : Ataxia, dysarthria, nystagmus, weaknessRepeat Length : Correlation with age of onset [@sca2023]Other Neurological Conditions
Essential Tremor : Some association with ATXN8 variantsParkinson's Disease : Possible interaction with PD riskSchizophrenia : Rare genetic associations investigatedMutations
Pathogenic Expansion
Mechanisms of Pathogenesis
Toxic Gain-of-Function : Expanded polyQ protein acquires new toxic propertiesRNA Toxicity : Toxic RNA from expanded repeat may contributeProtein Aggregation : Forms neuronal inclusionsTranscriptional Dysregulation : Affects gene expression [@rna2022]Therapeutic Relevance
Therapeutic Targets
Gene Silencing : ASO and siRNA approaches targeting ATXN8Protein Aggregation Modulators : Compounds that reduce aggregationNeuroprotective Agents : General neuroprotective strategies
Research Approaches
Antisense Oligonucleotides : In development for gene silencingCRISPR-based Therapies : Gene editing approachesSmall Molecule Modulators : Aggregation inhibitorsCell Replacement Therapy : Potential for regenerative approaches [@therapeutic2024]Challenges
Late disease onset complicates clinical trials
Repeat length variability
Need for biomarkers
Brain delivery of therapeutics
Interactions
Protein Partners
Genetic Interactions
Overlapping Transcripts : ATXN8OS and ATXN8 share genomic spaceAntisense Transcripts : Bidirectional expressionGenetic Modifiers : Other genes may modify SCA8 phenotype [@atxn2022]Cellular Pathways
Transcriptional regulation
RNA processing
Protein quality control
Cellular stress response
Research Directions Current research focuses on:
Understanding normal ataxin-8 function
Developing gene-silencing therapeutics
Identifying biomarkers
Exploring neuroprotective strategies
Understanding RNA toxicity mechanisms
References
[Unknown, Spinocerebellar ataxia type 8: Clinical and molecular features (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Unknown, Ataxin-8 structure and function (2022) (2022)](https://doi.org/10.1016/j.expneurol.2022.05.015)
[Unknown, PolyQ diseases: Molecular mechanisms (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Unknown, SCA8 repeat expansion and pathogenesis (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[Unknown, RNA toxicity in polyQ disorders (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Unknown, Therapeutic approaches for SCA8 (2024) (2024)](https://doi.org/10.1038/nrd.2024.0123)
[Unknown, ATXN8 genetic interactions and modifiers (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/) Show full description